Tysabri®
Effective Mar. 1, 2026, Tysabri will be removed from medical drug coverage, while its generic, tykuro, will be added to medical drug coverage for our commercial group and individual members.
How will this impact members?
- Current authorizations for Tysabri will be automatically transferred to tykuro for the duration of the member’s approval.
- Providers will need to submit a new order for tykuro to the site of service the impacted member received their Tysabri injections.
- This impacts 45 members.
What does it treat?
Both Tysabri and Tykuro are used to treat multiple sclerosis and Crohn’s disease.
Revlimid®
Effective Feb. 1, 2026, Revlimid will be removed from pharmacy benefit coverage for our commercial group and individual members and from our SaveOnSP drug list for members who participate in this program.
Revlimid’s generic, lenalidomide, is covered for our commercial group and individual members at Tier 4.
How will this impact members?
- Current authorizations for Revlimid will be automatically transferred to lenalidomide for the duration of the member’s approval.
- Those enrolled in SaveOnSP will no longer receive Revlimid at a $0 cost share.
- This change impacts 35 of our members.
What does it treat?
Both Revlimid and lenalidomide are used to treat certain types of blood cancer.